XW043H6 – Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6

Coding Notes

Active

Billable, valid for HIPAA-covered transactions

PCS Table

Section X New Technology
Body System W Anatomical Regions
Operation 0 Introduction
Body Part	Approach	Device / Substance / Technology	Qualifier
0 Skin	X External	2 Bromelain-enriched Proteolytic Enzyme	7 New Technology Group 7
1 Subcutaneous Tissue	3 Percutaneous	9 Satralizumab-mwge	7 New Technology Group 7
1 Subcutaneous Tissue	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5
1 Subcutaneous Tissue	3 Percutaneous	H Other New Technology Monoclonal Antibody K Leronlimab Monoclonal Antibody S COVID-19 Vaccine Dose 1 T COVID-19 Vaccine Dose 2 U COVID-19 Vaccine	6 New Technology Group 6
1 Subcutaneous Tissue	3 Percutaneous	W Caplacizumab	5 New Technology Group 5
1 Subcutaneous Tissue	X External	2 Bromelain-enriched Proteolytic Enzyme	7 New Technology Group 7
2 Muscle	3 Percutaneous	S COVID-19 Vaccine Dose 1 T COVID-19 Vaccine Dose 2 U COVID-19 Vaccine	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	0 Brexanolone 2 Nerinitide 3 Durvalumab Antineoplastic	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	5 Narsoplimab Monoclonal Antibody	7 New Technology Group 7
3 Peripheral Vein	3 Percutaneous	6 Lefamulin Anti-infective	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	6 Terlipressin	7 New Technology Group 7
3 Peripheral Vein	3 Percutaneous	7 Coagulation Factor Xa, Inactivated	2 New Technology Group 2
3 Peripheral Vein	3 Percutaneous	7 Trilaciclib 8 Lurbinectedin	7 New Technology Group 7
3 Peripheral Vein	3 Percutaneous	9 Defibrotide Sodium Anticoagulant	2 New Technology Group 2
3 Peripheral Vein	3 Percutaneous	9 Ceftolozane/Tazobactam Anti-infective	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	A Bezlotoxumab Monoclonal Antibody	3 New Technology Group 3
3 Peripheral Vein	3 Percutaneous	A Cefiderocol Anti-infective	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	A Ciltacabtagene Autoleucel	7 New Technology Group 7
3 Peripheral Vein	3 Percutaneous	B Cytarabine and Daunorubicin Liposome Antineoplastic	3 New Technology Group 3
3 Peripheral Vein	3 Percutaneous	B Omadacycline Anti-infective	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	B Amivantamab Monoclonal Antibody	7 New Technology Group 7
3 Peripheral Vein	3 Percutaneous	C Eculizumab	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous	7 New Technology Group 7
3 Peripheral Vein	3 Percutaneous	D Atezolizumab Antineoplastic	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	E Remdesivir Anti-infective	5 New Technology Group 5
3 Peripheral Vein	3 Percutaneous	E Etesevimab Monoclonal Antibody	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	3 New Technology Group 3
3 Peripheral Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5
3 Peripheral Vein	3 Percutaneous	F Bamlanivimab Monoclonal Antibody	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	G Plazomicin Anti-infective	4 New Technology Group 4
3 Peripheral Vein	3 Percutaneous	G Sarilumab	5 New Technology Group 5
3 Peripheral Vein	3 Percutaneous	G REGN-COV2 Monoclonal Antibody	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic	7 New Technology Group 7
3 Peripheral Vein	3 Percutaneous	H Synthetic Human Angiotensin II	4 New Technology Group 4
3 Peripheral Vein	3 Percutaneous	H Tocilizumab	5 New Technology Group 5
3 Peripheral Vein	3 Percutaneous	H Other New Technology Monoclonal Antibody	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	H Axicabtagene Ciloleucel Immunotherapy J Tisagenlecleucel Immunotherapy	7 New Technology Group 7
3 Peripheral Vein	3 Percutaneous	K Fosfomycin Anti-infective	5 New Technology Group 5
3 Peripheral Vein	3 Percutaneous	K Idecabtagene Vicleucel Immunotherapy	7 New Technology Group 7
3 Peripheral Vein	3 Percutaneous	L CD24Fc Immunomodulator	6 New Technology Group 6
3 Peripheral Vein	3 Percutaneous	L Lifileucel Immunotherapy M Brexucabtagene Autoleucel Immunotherapy	7 New Technology Group 7
3 Peripheral Vein	3 Percutaneous	N Meropenem-vaborbactam Anti-infective	5 New Technology Group 5
3 Peripheral Vein	3 Percutaneous	N Lisocabtagene Maraleucel Immunotherapy	7 New Technology Group 7
3 Peripheral Vein	3 Percutaneous	Q Tagraxofusp-erzs Antineoplastic S Iobenguane I-131 Antineoplastic U Imipenem-cilastatin-relebactam Anti-infective W Caplacizumab	5 New Technology Group 5
4 Central Vein	3 Percutaneous	0 Brexanolone 2 Nerinitide 3 Durvalumab Antineoplastic	6 New Technology Group 6
4 Central Vein	3 Percutaneous	5 Narsoplimab Monoclonal Antibody	7 New Technology Group 7
4 Central Vein	3 Percutaneous	6 Lefamulin Anti-infective	6 New Technology Group 6
4 Central Vein	3 Percutaneous	6 Terlipressin	7 New Technology Group 7
4 Central Vein	3 Percutaneous	7 Coagulation Factor Xa, Inactivated	2 New Technology Group 2
4 Central Vein	3 Percutaneous	7 Trilaciclib 8 Lurbinectedin	7 New Technology Group 7
4 Central Vein	3 Percutaneous	9 Defibrotide Sodium Anticoagulant	2 New Technology Group 2
4 Central Vein	3 Percutaneous	9 Ceftolozane/Tazobactam Anti-infective	6 New Technology Group 6
4 Central Vein	3 Percutaneous	A Bezlotoxumab Monoclonal Antibody	3 New Technology Group 3
4 Central Vein	3 Percutaneous	A Cefiderocol Anti-infective	6 New Technology Group 6
4 Central Vein	3 Percutaneous	A Ciltacabtagene Autoleucel	7 New Technology Group 7
4 Central Vein	3 Percutaneous	B Cytarabine and Daunorubicin Liposome Antineoplastic	3 New Technology Group 3
4 Central Vein	3 Percutaneous	B Omadacycline Anti-infective	6 New Technology Group 6
4 Central Vein	3 Percutaneous	B Amivantamab Monoclonal Antibody	7 New Technology Group 7
4 Central Vein	3 Percutaneous	C Eculizumab	6 New Technology Group 6
4 Central Vein	3 Percutaneous	C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous	7 New Technology Group 7
4 Central Vein	3 Percutaneous	D Atezolizumab Antineoplastic	6 New Technology Group 6
4 Central Vein	3 Percutaneous	E Remdesivir Anti-infective	5 New Technology Group 5
4 Central Vein	3 Percutaneous	E Etesevimab Monoclonal Antibody	6 New Technology Group 6
4 Central Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	3 New Technology Group 3
4 Central Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5
4 Central Vein	3 Percutaneous	F Bamlanivimab Monoclonal Antibody	6 New Technology Group 6
4 Central Vein	3 Percutaneous	G Plazomicin Anti-infective	4 New Technology Group 4
4 Central Vein	3 Percutaneous	G Sarilumab	5 New Technology Group 5
4 Central Vein	3 Percutaneous	G REGN-COV2 Monoclonal Antibody	6 New Technology Group 6
4 Central Vein	3 Percutaneous	G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic	7 New Technology Group 7
4 Central Vein	3 Percutaneous	H Synthetic Human Angiotensin II	4 New Technology Group 4
4 Central Vein	3 Percutaneous	H Tocilizumab	5 New Technology Group 5
4 Central Vein	3 Percutaneous	H Other New Technology Monoclonal Antibody	6 New Technology Group 6
4 Central Vein	3 Percutaneous	H Axicabtagene Ciloleucel Immunotherapy J Tisagenlecleucel Immunotherapy	7 New Technology Group 7
4 Central Vein	3 Percutaneous	K Fosfomycin Anti-infective	5 New Technology Group 5
4 Central Vein	3 Percutaneous	K Idecabtagene Vicleucel Immunotherapy	7 New Technology Group 7
4 Central Vein	3 Percutaneous	L CD24Fc Immunomodulator	6 New Technology Group 6
4 Central Vein	3 Percutaneous	L Lifileucel Immunotherapy M Brexucabtagene Autoleucel Immunotherapy	7 New Technology Group 7
4 Central Vein	3 Percutaneous	N Meropenem-vaborbactam Anti-infective	5 New Technology Group 5
4 Central Vein	3 Percutaneous	N Lisocabtagene Maraleucel Immunotherapy	7 New Technology Group 7
4 Central Vein	3 Percutaneous	Q Tagraxofusp-erzs Antineoplastic S Iobenguane I-131 Antineoplastic U Imipenem-cilastatin-relebactam Anti-infective W Caplacizumab	5 New Technology Group 5
9 Nose	7 Via Natural or Artificial Opening	M Esketamine Hydrochloride	5 New Technology Group 5
D Mouth and Pharynx	X External	6 Lefamulin Anti-infective	6 New Technology Group 6
D Mouth and Pharynx	X External	8 Uridine Triacetate	2 New Technology Group 2
D Mouth and Pharynx	X External	F Other New Technology Therapeutic Substance J Apalutamide Antineoplastic L Erdafitinib Antineoplastic	5 New Technology Group 5
D Mouth and Pharynx	X External	M Baricitinib	6 New Technology Group 6
D Mouth and Pharynx	X External	R Venetoclax Antineoplastic T Ruxolitinib V Gilteritinib Antineoplastic	5 New Technology Group 5
G Upper GI H Lower GI	7 Via Natural or Artificial Opening	M Baricitinib	6 New Technology Group 6
G Upper GI H Lower GI	8 Via Natural or Artificial Opening Endoscopic	8 Mineral-based Topical Hemostatic Agent	6 New Technology Group 6
Q Cranial Cavity and Brain	3 Percutaneous	1 Eladocagene exuparvovec	6 New Technology Group 6
V Bones	0 Open	P Antibiotic-eluting Bone Void Filler	7 New Technology Group 7

Sibling Codes

XW0.43H4

Introduction of Synthetic Human Angiotensin II into Central Vein, Percutaneous Approach, New Technology Group 4

XW0.43H5

Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5

XW0.43H7

Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7